U pper limb hemiplegia after stroke remains a significant clinical challenge in rehabilitation because only 20% of patients recover normal hand function. 1 There is a growing interest in the use of noninvasive neuromodulation combined with standard upper limb rehabilitation for functional restoration in patients with poststroke hemiplegia. 2, 3 Of the various types of neuromodulation available, low-frequency repetitive transcranial magnetic stimulation (rTMS) to the noninjured hemisphere has reasonable proof of principle. 4 Low-frequency motor cortex stimulation can reduce neuronal excitability within targeted cortex. Based on the theory of interhemispheric inhibition, downregulation of hyperexcitable noninjured cortex can reduce transcallosal inhibitory drive to the hypoactive residual corticospinal system of the injured hemisphere. 5 A return of balance in cortical excitability between the 2 hemispheres is associated with superior motor recovery poststroke and may be necessary to achieve functional motor return. 6, 7 Small randomized trials have supported the efficacy of l Hz rTMS to the noninjured hemisphere, demonstrating improvements in finger tapping, pinch force, and hand acceleration. 8, 9 Motor improvement after 1 Hz rTMS to noninjured hemisphere is associated with corticospinal excitability changes in perilesional cortex, which further validates this approach. 5 Here, we delivered rTMS with a rehabilitation motor training protocol using a navigated brain therapy device (NBT; Nexstim Plc, Helsinki, Finland) which improves clinical utility through a novel brain mapping approach, simplifying identification of cortical targets and storing those targets for repeated therapy sessions over a course of treatment. 10 Our goal was to assess whether low-frequency rTMS delivered to the noninjured hemisphere motor cortex by NBT before task-oriented upper limb therapy can improve motor gains measured by the upper extremity Fugl-Meyer (UEFM) score better than sham NBT avoiding motor cortex when combined with the same motor training. We hypothesized that patients receiving targeted NBT and rehabilitation would more likely achieve meaningful improvement in motor impairment and function.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request.
Trial Design
This was a multicenter randomized, blinded, sham-controlled pivotal trial comparing NBT comprising 1 Hz rTMS to noninjured hemisphere versus sham stimulation, delivered before upper limb rehabilitation therapy. Random assignment of participants occurred at 12 sites in the United States in a 2:1 ratio of experimental treatment to sham. An imbalanced randomization provided adequate subject exposure to therapeutic NBT for assessment of safety. Blinding to group assignment included all participants and study staff except for the NBT device operator. After institutional review board approvals at each site, participants provided written informed consent before any study-related activity. Study oversight included a clinical research organization (Clinipace Worldwide, Morrisville, NC), a medical monitor used by the study sponsor, and an independent data safety monitoring board. A statistical analysis plan included 2 interim analyses with early stopping rules based on statistical efficacy and futility.
Participants
Participants included patients 18 years of age or older with unilateral ischemic or hemorrhagic stroke within 3 to 12 months of enrollment and with a Chedoke assessment stage of 3 to 6 for both arm and hand. For additional details, see the online-only Data Supplement.
Intervention and Instrumentation
Enrolled participants underwent structural cranial magnetic resonance imaging used for NBT target localization. Baseline upper limb performance was measured before the start of therapy, and NBT motor mapping was completed for both hemispheres. After randomization, participants received 18 treatment sessions, typically 3× per week, over a 6-week period. An additional week was permitted to replace missed sessions. Therapy sessions began with 20 minutes of prefunctional upper limb therapy focusing on basic shoulder and elbow mobilization graded according to participants' current Chedoke arm stage. After a 10-minute rest, NBT was delivered to the noninjured hemisphere >15 minutes per assigned protocol. NBT was delivered using 1 Hz frequency to the cortical target on noninjured hemisphere. The sham coil provided no stimulating E-field at the target site but instead delivered weak E-fields in a wide doughnut-shape region around the target area avoiding stimulation to motor cortex (Figure 1) . After a 5-to 15-minute rest, participants engaged in a structured 60-minute session of goal-directed, task-oriented rehabilitation therapy. Therapy focused on arm and hand practice with meaningful functional tasks selected by the patient and therapist and graded for skill level based on participant's current Chedoke hand stage. Outcome measures were collected at 1 week and 1, 3, and 6 months after end of treatment (EOT). Details about permitted activities and rehabilitation during the follow-up period and the NBT system used are provided in the online-only Data Supplement.
Outcome Measures
Primary and secondary measures were collected by nontreating clinician raters, masked to treatment assignment, and trained by a single rater. Raters were reassessed every 6 months on the primary outcome and key secondary outcomes to maintain standardization throughout the duration of the study.
The primary outcome of interest was change in UEFM score between baseline measurement and 6-month follow-up after EOT. The validity and reliability of the UEFM have been demonstrated, [11] [12] [13] and it is considered to be a good measure of motor impairment in stroke research. 14 The primary end point was defined as the percentage of patients (responders) with a clinically meaningful improvement in UEFM score assessed 6 months posttreatment. A clinically meaningful improvement was defined a priori as a 5-point improvement from the baseline UEFM score. 15 Secondary measures included the absolute change on the UEFM at each posttreatment time point, as well as change on the Action Research Arm Test (ARAT) and the Wolf Motor Function Test (WMFT) testing hand speed and dexterity. Physical functioning and participation were measured using the Stroke Impact Scale-16, and quality of life using the EuroQol-5D instrument. National Institutes Health Stroke Scale, and Patient Health Questionnaire-9 were measured as safety measures of neurological status and mood, respectively, throughout the study. Other baseline measures included the modified Ashworth score for spasticity at shoulder, elbow, wrist, and fingers and the mini-mental status examination. All expected and unexpected adverse events were monitored and recorded throughout the trial. Expected adverse reactions to NBT included headaches, changes in hearing, skin irritation from electrodes, and seizures. Expected adverse reactions to the rehabilitation therapy protocol and motor outcome assessments included upper limb soreness and fatigue.
Sample Size, Randomization, and Blinding
A group sequential design 16 with 3 stages was used to calculate sample size. The 3 stages represent 2 interim analyses testing for efficacy or futility according to predefined criteria. Critical values were selected for stopping the trial early based on the probability of rejecting the null hypothesis using the standardized 2-tailed Z test statistic. Both type 1 and type 2 errors were held at 0.05, providing a 95% power to detect treatment effect. Using unpublished pilot data collected before this study (N=15) showing an 80% response rate with rTMS (UEFM ≥5-point change) versus a 40% response rate in sham (a 40% absolute difference), it was estimated that a minimum of 81 patients were needed to reject the null hypothesis, with 90% power, at the first interim analysis. A larger sample of 138 at a second interim could reject the null hypothesis with a 30% difference between groups at 88% power. Increasing the sample size to 198 patients in a final analysis would detect a 30% difference with a 94.5% power.
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Randomization was achieved using a random number generator, leading to a treatment and sham assignment in a 2:1 ratio and blocked by site and time since stroke (3-6 versus >6 months poststroke).
Only the NBT system operator was aware of treatment group assignment and handled treatment and sham coils. All administrative staff, treating and outcome raters remained blinded to group assignment throughout the trial.
Statistical Analysis
The primary efficacy analysis was generated from the intent-totreat population, with a separate calculation conducted on the perprotocol population. The safety population consisted only of those who received study treatments. Missing values were imputed using the last observation carried forward principle. Details about measurement of effect size, between-group changes, comparison tests, other secondary measures (ARAT, WMFT, Stroke Impact Scale, EQ-5D, National Institutes Health Stroke Scale, and Patient Health Questionnaire-9), and primary efficacy analysis are described in the online-only Data Supplement.
Results
From May 2014 to December 2015, we screened 1157 patients for the study. There were 958 who either did not meet inclusion criteria, met ≥1 exclusion criteria, or declined to participate. A participant flow diagram through the study is presented in Figure 2 . Although the target sample size was achieved, follow-up was not completed after the Data Safety Monitoring Board reported on February 26, 2016 , that the second interim analysis met statistical futility for the intervention. Data collection was terminated on May 6, 2016, and final data points were not collected on the last 26 enrolled participants (19 active and 7 sham). Six-month follow-up values were not imputed forward for the early terminated subgroup. All other participants lost to followup were included in the final analysis, with last measures carried forward. Thus, 199 subjects were enrolled in the intent-to-treat sample (132 active, 67 sham), with 6-month outcome data available for 173 (113 active and 60 sham).
Because of 3 participants withdrawing before study interventions, the safety sample is 196. The per-protocol sample was 169 after removing 30 subjects with significant protocol deviations (15 active and 15 sham). Table 1 summarizes the baseline characteristics of the study participants. The mean (±SD) age of the participants was 58.7±13.1 years; 65.3% were men and 23.7% were black. There were 78.9% ischemic strokes, and most subjects (71.4%) were >6 to 12 months poststroke. Of those with ischemic injury, 26.1% were located in cortex, 35.6% were subcortical, 15.2% included both cortex and subcortex, and 22.9% were located in brain stem. Subcortical strokes included the centrum semiovale or corona radiata (24.2%), basal ganglia (26.1%), internal capsule (22.9%), and thalamus (10.1%). The majority of brain stem strokes were located in the pons. Of those with injury related to brain hemorrhage, 9.7% were cortical, 75.6% were subcortical, 9.7% involved both cortex and subcortex, and 4.8% were within the brain stem. All participants met inclusion criteria for Chedoke arm and hand stage of 3 to 6 and most were stage 3 to 4. The mean baseline UEFM was 34.3 falling in the moderately severe range of motor impairment (21-50). The mean ARAT score was 28.2, and the mean WMFT score was 31.2. 
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September 2018 Mean values for outcome measures at baseline, EOT, and follow-up are listed in Table 2 . Participants in both active and sham groups had significant improvements in all measures at all follow-up points. At 6 months after treatment, there was an overall 66% response rate, with 114 of 173 participants achieving a clinically meaningful improvement on the UEFM from baseline. The primary end point was not met in the intent-to-treat population. At 6-month follow-up, there were 76 responders or 67% (95% CI, 58%-75%) in the active group and 39 responders or 65% (95% CI, 52%-76%) in the sham group (P=0.76). Time since stroke had no impact on 6-month outcomes. There was no significant difference in the outcome with the per-protocol cohort.
Secondary end points also were not met, as shown in Within-group changes in all measures were significantly improved at the end of study (P<0.001; Table 2 ; Table I in the online-only Data Supplement). Spasticity as measured by the modified Ashworth score did not change during treatment.
Of patients with ischemic stroke, 71% (95% CI, 63%-78%) achieved a clinically meaningful change on the UEFM at 6 months, compared with 50% (95% CI, 35%-65%), with hemorrhagic stroke within the intent-to-treat sample (P=0.016). Active and sham groups had no difference in rate of successful response according to stroke cause. Participants with hemorrhagic stroke who received active treatment had better-measured change at end of study than sham for UEFM (8.4±8.0 active versus 4.5±6.0 sham; P=0.016), ARAT (5.5±8.7 active versus 1.8±10.8 sham; P=0.048), and WMFT (−6.2±21.9 active versus 5.9±35.4 sham; P=0.039). Only change on UEFM reached statistical significance after Bonferroni correction. In covariate analysis, neither the presence of mild depressive symptoms (Patient Health Questionnaire-9) nor the amount of occupational therapy hours between EOT and 6 months posttreatment had any impact on outcome or response to treatment. The effectiveness of blinding was successful among participants and outcome assessors. Approximately 70% of participants believed they received active treatment regardless of group assignment (P=0.69). The majority (≈75%) of assessors were unable to identify a treatment arm for subjects, and they were similarly inaccurate when they did choose a treatment arm (P=0.89).
Of the safety population (n=196), a total of 26 serious adverse events occurred in 18 participants. Rates within treatment arms were not significantly different. The most common treatment-related adverse events were arm and hand pain, spasm or myalgia (n=14), head discomfort (n=11), and paresthesia (n=6). These were transient and resolved within 24 hours of onset. Additional safety information is available in the online-only Data Supplement.
Discussion
This is the largest randomized, sham-controlled, clinical trial of low-frequency navigated brain stimulation for stroke recovery to date. Participants in both study arms showed significant improvement in the UEFM at 6-month follow-up, exceeding the expected arm and hand recovery for patients 3 to 12 months after stroke. Our findings did not support the hypothesis that navigated rTMS to noninjured motor cortex in patients with stroke results in better arm and hand recovery 6 months after treatment. We also found no evidence of efficacy at any measured time point after therapy. These findings indicate either a lack of efficacy of adding rTMS to rehabilitation therapy or that both stimulation protocols facilitated the outcomes achieved in this trial. Participants with hemorrhagic stroke showed only modest improvement, but those who received targeted rTMS rather than sham demonstrated significantly greater gains in motor recovery. The clinical importance of this finding is uncertain given the small number with hemorrhagic stroke; it does suggest that motor cortex stimulation in patients with intracerebral hemorrhage should be investigated further.
The rationale of targeting the unaffected cortex was to diminish the pathological intracortical excitability observed 
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in poststroke hemiparesis. [17] [18] [19] Targeting the undamaged hemisphere has a low risk of inducing seizure and has no impact on motor behavior in the healthy corticospinal system. 20 We combined rTMS with behavioral therapy to enhance the efficacy relative to either intervention alone as supported by our pilot study. 21, 22 A lack of difference between experimental treatment and sham does not imply that rTMS has no role in improving stroke recovery. Other rTMS protocols such as high-frequency stimulation to the injured hemisphere or low-frequency stimulation at other target sites in the noninjured hemisphere might be effective, 23 or treatment of more acute stroke population (<3 months poststroke) might show different results. 24 The capacity for motor recovery and response to rTMS therapy may be governed by location and severity of stroke-related damage. In particular, lesion load to the corticospinal tract predicts recovery. 25 Single-pulse TMS might be useful to confirm functional motor connectivity in individuals who might best respond to treatment. 26, 27 A majority of our study cohort exhibited significant improvements in motor ability immediately after therapy to 6 months after EOT, supporting the effectiveness of upper-limb therapy. The rehabilitation provided was goal-directed, taskoriented, and focused on skilled movements of arm and hand, which is currently considered to be the best evidence-based treatment for hemiplegia. 28 The impact of motor practice on recovery in our relatively young (mean age <60 years) population might have exceeded any effect of electromagnetically induced cortical modulation. Alternatively, cortical modulation may have enhanced motor outcomes because of efficacy of both treatment and sham stimulation.
The sham coil was of a unique design intended to provide only sensory stimulation over scalp and cortex by a donutshaped weak electric field (Figure 1 ). The annulus of this donut avoided the treatment site with a low-intensity electric field (10-30 V/m) over a surrounding area 20 to 40 times larger than the targeted motor cortex location. At the time of the trial design, consensus was that a widely dispersed lowelectric field would not induce neural modulation; however, recent work suggests that low electric fields can modulate cortex. For example, in vitro studies of L5 pyramidal neurons exposed to rTMS with similarly low field strength (0.09 T) induced altered neuronal excitability up to 20 minutes after stimulation. 29 In humans, rTMS-induced electric fields as low as 5 V/m have led to similar electroencephalogram changes as observed with higher electric fields, providing evidence that low electric field strengths can influence cortical activity. 30 Our sham coil stimulus may have induced neurons toward firing threshold in synchrony 31 and in turn induced lateral inhibition to the target motor area within the donut hole, the site where active coil inhibitory stimulation was also delivered. Thus, cortical modulation at the target site may have been similar with both coils. 32 Comparison of the locally targeted coil with a sham delivering no electric field to cortex would clarify whether traditional low-frequency rTMS enhances recovery. This trial is ongoing.
Serious adverse events in this study were those commonly observed among patients with stroke and were not different between treatment groups, supporting the safety of rTMS in both patients with ischemic and hemorrhagic stroke when delivered according to established guidelines, as has been previously suggested in 2 meta-analyses. 33, 34 In addition to concerns about the impact of low-threshold cortical stimulation with the sham coil, this study has other limitations. We recruited subjects 3 to 12 months poststroke who had received acute care at various medical centers unassociated with the study sites. As such, the availability of acute hospital records was limited, and we could not accurately characterize participants' stroke risk factors, acute stroke management, and certain other comorbid characteristics except by reported history, which may not be fully reliable. In addition, we were unable to perform detailed analysis of magnetic resonance images for stroke location and volume. Although lesion volume is a weak predictor of response to therapy targeting upper limb recovery, injury to descending tracts from the primary motor and premotor cortices do correlate with therapeutic efficacy. 35 Differential lesion involvement of these tracts could have influenced our results.
We conclude that this trial does not support the superiority of navigated rTMS targeted to noninjured hemisphere motor cortex over our sham rTMS protocol that avoided targeting motor cortex when combined with optimized rehabilitation among patients 3 to 12 months poststroke. Goaldirected arm and hand therapy does improve recovery, and the improvement observed in our participants was higher than expected, supporting the possibility that both cortical stimulation types used in this trial may provide adjuvant treatment for motor recovery. Further research is now underway to test motor cortex targeted rTMS against a sham coil that does not stimulate cortex.
